Bioxcel Therapeutics Stock Probability of Future Stock Price Finishing Over 0.68

BTAI Stock  USD 0.44  0  0.23%   
BioXcel Therapeutics' future price is the expected price of BioXcel Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of BioXcel Therapeutics performance during a given time horizon utilizing its historical volatility. Check out BioXcel Therapeutics Backtesting, BioXcel Therapeutics Valuation, BioXcel Therapeutics Correlation, BioXcel Therapeutics Hype Analysis, BioXcel Therapeutics Volatility, BioXcel Therapeutics History as well as BioXcel Therapeutics Performance.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
  
The current Price To Sales Ratio is estimated to decrease to 59.16. The current Price Earnings Ratio is estimated to decrease to -0.5. Please specify BioXcel Therapeutics' target price for which you would like BioXcel Therapeutics odds to be computed.

BioXcel Therapeutics Target Price Odds to finish over 0.68

The tendency of BioXcel Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 0.68  or more in 90 days
 0.44 90 days 0.68 
about 9.23
Based on a normal probability distribution, the odds of BioXcel Therapeutics to move over $ 0.68  or more in 90 days from now is about 9.23 (This BioXcel Therapeutics probability density function shows the probability of BioXcel Stock to fall within a particular range of prices over 90 days) . Probability of BioXcel Therapeutics price to stay between its current price of $ 0.44  and $ 0.68  at the end of the 90-day period is about 84.92 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.5 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, BioXcel Therapeutics will likely underperform. Additionally BioXcel Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   BioXcel Therapeutics Price Density   
       Price  

Predictive Modules for BioXcel Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioXcel Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.020.447.20
Details
Intrinsic
Valuation
LowRealHigh
0.020.427.18
Details
Naive
Forecast
LowNextHigh
0.010.507.26
Details
4 Analysts
Consensus
LowTargetHigh
16.5818.2220.22
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as BioXcel Therapeutics. Your research has to be compared to or analyzed against BioXcel Therapeutics' peers to derive any actionable benefits. When done correctly, BioXcel Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in BioXcel Therapeutics.

BioXcel Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BioXcel Therapeutics is not an exception. The market had few large corrections towards the BioXcel Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioXcel Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioXcel Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.3
β
Beta against Dow Jones1.50
σ
Overall volatility
0.08
Ir
Information ratio -0.04

BioXcel Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioXcel Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioXcel Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BioXcel Therapeutics generated a negative expected return over the last 90 days
BioXcel Therapeutics has high historical volatility and very poor performance
BioXcel Therapeutics has some characteristics of a very speculative penny stock
BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 355 K.
BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 20.0% of the company shares are held by company insiders
Latest headline from globenewswire.com: BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering

BioXcel Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioXcel Stock often depends not only on the future outlook of the current and potential BioXcel Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioXcel Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding29.1 M
Cash And Short Term Investments65.2 M

BioXcel Therapeutics Technical Analysis

BioXcel Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. BioXcel Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of BioXcel Therapeutics. In general, you should focus on analyzing BioXcel Stock price patterns and their correlations with different microeconomic environments and drivers.

BioXcel Therapeutics Predictive Forecast Models

BioXcel Therapeutics' time-series forecasting models is one of many BioXcel Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BioXcel Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about BioXcel Therapeutics

Checking the ongoing alerts about BioXcel Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for BioXcel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BioXcel Therapeutics generated a negative expected return over the last 90 days
BioXcel Therapeutics has high historical volatility and very poor performance
BioXcel Therapeutics has some characteristics of a very speculative penny stock
BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 355 K.
BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 20.0% of the company shares are held by company insiders
Latest headline from globenewswire.com: BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.04)
Revenue Per Share
0.074
Quarterly Revenue Growth
1.416
Return On Assets
(0.64)
Return On Equity
(17.67)
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.